# Medical Question & Answer

**Sample ID**: 48561e76-6c9e-4d8b-9a3a-559545d5eacd
**Dataset Index**: 4549

---

## Question

how does aspirin improve wound healing in someone with chronic venous insufficiency? Is it due to supporting venous flow?

---

## Answer

> Let's see… What do we have here? The user is asking how aspirin improves wound healing in chronic venous insufficiency and venous leg ulcers, and whether this effect is related to supporting venous flow. Let's break this down step-by-step. First, I need to think about the pathophysiology of venous leg ulcers and what actually drives healing. Then, I should verify what major guidelines say about aspirin or antiplatelet therapy for ulcer healing. Next, I will examine whether any provided sources directly link aspirin to improved venous flow or ulcer outcomes. After that, I should consider indirect or theoretical mechanisms and whether they are supported by evidence. Finally, I will synthesize a conclusion and outline evidence-based therapies that do improve healing, making sure I double-check for any conflicting data I might have missed.

> Let me first confirm the disease mechanism. Venous leg ulcers arise from sustained venous hypertension due to reflux and/or obstruction, which injures the microcirculation, promotes a proinflammatory milieu with high matrix metalloproteinase activity, impairs fibroblast function, and creates a fibrin cuff that limits oxygen and nutrient diffusion. Healing requires correction of venous hypertension, wound bed preparation, and restoration of a permissive molecular environment, not simply antiplatelet effects [^112CpX8n] [^1145zHJQ].

> Wait, let me verify guideline positions on aspirin for venous ulcer healing. The Society for Vascular Surgery/American Venous Forum guideline explicitly recommends against anti-inflammatory therapies for venous leg ulcers, and aspirin is not listed among recommended therapies for ulcer healing; instead, the cornerstone is compression therapy with adjuncts like pentoxifylline or micronized purified flavonoid fraction for refractory cases, and procedural correction of superficial reflux when indicated [^115hA5Vb] [^114byCVa] [^112xTcaL] [^114X9ArX].

> Hold on, I should check whether any of the provided documents directly connect aspirin to improved venous flow or ulcer healing. I need to ensure I'm not overlooking a trial or recommendation. After reviewing the FDA aspirin labeling and the venous disease guidelines, I find no indication for aspirin to treat venous leg ulcers or to enhance venous return; aspirin's vascular indications are arterial (e.g., secondary prevention of MI/stroke, PAD), not venous ulcer healing, and the venous guidelines do not include aspirin as a therapy for VLUs [^112PpSbE] [^115hA5Vb].

> Let me consider indirect or theoretical mechanisms. Aspirin irreversibly inhibits platelet COX-1, reducing thromboxane A2 and platelet aggregation; in theory, that could modulate microthrombi or inflammation, but venous ulcer pathophysiology is primarily driven by venous hypertension and extracellular matrix remodeling rather than platelet-driven thrombosis, so antiplatelet effects alone would not correct the underlying disease process; moreover, there is no evidence here that aspirin improves calf muscle pump function, reduces reflux, or lowers ambulatory venous pressure, which are the hemodynamic drivers of healing [^112CpX8n] [^1115tsQ8].

> Hmm, wait a minute — could I be conflating arterial and venous limb ischemia guidance? Initially, I wondered if antiplatelet therapy might help ischemic ulcers broadly, but I should confirm the distinction. The antiplatelet recommendations and meta-analyses showing reduced serious vascular events pertain to arterial disease and graft patency, not venous leg ulcers; in fact, even in critical limb ischemia, antiplatelet therapy is for cardiovascular risk reduction and graft patency, with wound healing strategies focused on revascularization and offloading, underscoring that aspirin does not treat the cause of venous ulcers [^114YLaro] [^112P7ha7] [^115wMUo4].

> I should double-check what actually improves venous ulcer healing so I don't leave the question hanging. Compression therapy is first-line and strongly recommended to increase healing rates and reduce recurrence; if ulcers fail to improve after 4–6 weeks of standard care, adjuncts such as pentoxifylline or micronized purified flavonoid fraction can be considered with continued compression; and correction of superficial reflux with ablation or surgery reduces recurrence and can accelerate healing in selected patients, all of which target venous hypertension rather than platelet function [^112xTcaL] [^114byCVa] [^113tbfgu] [^114X9ArX].

> But wait, what if the patient also has arterial disease or is on anticoagulation — does that change things? I need to ensure safety. In mixed disease, compression must be individualized and avoided if ABI is very low; aspirin may be indicated for arterial indications or VTE prevention strategies, yet that still does not translate into a venous ulcer healing benefit, reinforcing that aspirin's role, if present, is unrelated to venous flow mechanics or ulcer pathobiology [^11472gLG] [^113udtMh].

> Synthesis and conclusion: I should confirm the bottom line. There is no evidence in the provided sources that aspirin improves wound healing in chronic venous insufficiency or venous leg ulcers, and no guideline endorsement of aspirin for this purpose. Any theoretical antiplatelet or anti-inflammatory effect does not address the core problem of venous hypertension and matrix remodeling, so aspirin should not be used to promote venous ulcer healing, whereas compression, wound bed preparation, and correction of reflux are the evidence-based pathways to improved outcomes [^115hA5Vb] [^112xTcaL] [^114byCVa].

---

Aspirin does not improve wound healing in chronic venous insufficiency (CVI) by supporting venous flow. There is **no evidence** that aspirin enhances venous return or reduces venous hypertension, and it is **not recommended** for venous ulcer healing [^115hA5Vb]. The mainstay of CVI wound care is **compression therapy** [^112xTcaL] [^115Rmpjw], with adjuncts such as pentoxifylline or micronized purified flavonoid fraction when needed [^114byCVa] [^117XyRQ5]. Aspirin's antiplatelet effects do not address the pathophysiology of CVI-related ulcers, and its use may increase bleeding risk without proven benefit.

---

## Pathophysiology of chronic venous insufficiency and wound healing

CVI is characterized by **venous hypertension** from valvular incompetence and reflux, causing edema, skin changes, and ulcers [^1115tsQ8]. Key mechanisms impairing healing include:

- **Persistent venous hypertension**: Reduces perfusion and oxygen delivery, causing hypoxia and tissue damage [^112CpX8n].

- **Inflammation and fibrosis**: Chronic inflammation, extracellular matrix remodeling, and fibrosis further impair healing [^112CpX8n].

- **Microcirculatory dysfunction**: Endothelial dysfunction and microthrombi worsen ischemia and delay healing [^notfound].

---

## Mechanism of action of aspirin

Aspirin **irreversibly inhibits COX-1**, reducing thromboxane A2 and platelet aggregation, thereby lowering thrombotic risk [^115y9Nv7]. It is used for arterial indications (e.g. PAD, coronary disease) but does not improve venous return or reduce venous hypertension.

---

## Evidence regarding aspirin and wound healing in CVI

There is **no evidence** that aspirin improves venous return, reduces venous hypertension, or enhances healing in CVI-related ulcers. Major guidelines do not recommend aspirin for venous ulcer healing [^notfound]. While antiplatelet therapy reduces arterial events, it does not address venous hypertension or microcirculatory dysfunction in CVI [^114YLaro].

---

## Clinical guidelines and recommendations

Guidelines emphasize **compression therapy** as first-line to reduce edema and improve healing [^112xTcaL] [^115Rmpjw]. Adjuncts such as pentoxifylline or micronized purified flavonoid fraction may be used for refractory ulcers [^114byCVa] [^117XyRQ5]. Aspirin is not recommended for venous ulcer healing [^notfound].

---

## Potential risks and limitations of aspirin use in CVI

Aspirin carries **bleeding risk**, including gastrointestinal bleeding, which may outweigh any theoretical benefit in CVI ulcers. It does not address venous hypertension or microcirculatory dysfunction, limiting its utility in CVI wound healing.

---

## Alternative pharmacological and non-pharmacological interventions

Effective therapies include:

| **Intervention** | **Mechanism of action** | **Evidence level** |
|-|-|-|
| Compression therapy | Reduces edema, improves venous return, and promotes healing | Strong (Grade 1A) [^112xTcaL] [^112vhq8R] |
| Pentoxifylline | Improves microcirculation and oxygen delivery | Moderate (Grade 1B) [^114byCVa] |
| Micronized purified flavonoid fraction (MPFF) | Reduces inflammation and edema | Moderate (Grade 1B) [^114byCVa] |
| Endovenous ablation | Corrects venous reflux, reduces venous hypertension | Strong (Grade 1A) [^notfound] |

---

Aspirin does not improve wound healing in CVI by supporting venous flow; it is **not recommended** for venous ulcers, and care should focus on compression and evidence-based adjuncts.

---

## References

### The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum [^1116VCaT]. Journal of Vascular Surgery (2011). Medium credibility.

Outcome assessment in chronic venous disease — Outcome assessment of therapy of varicose veins and more advanced CVD includes standardized objective criteria that reflect patient symptoms, characteristic signs, and objective measures of functional and disease-specific QOL.

---

### 2016 AHA / ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary [^112xWUn7]. Vascular Medicine (2017). Medium credibility.

2016 AHA/ACC guideline — Management of critical limb ischemia (CLI): Patients with CLI are at increased risk of amputation and major cardiovascular ischemic events, and care includes evaluation for revascularization and wound healing therapies with the objective to minimize tissue loss, completely heal wounds, and preserve a functional foot. Medical therapy to prevent cardiovascular ischemic events is also an important component of care for the patient with CLI.

---

### Nonsurgical management of chronic venous insufficiency [^116DmLqg]. The New England Journal of Medicine (2024). Excellent credibility.

The disease chronic venous insufficiency can be associated with venous leg ulcer, leg telangiectasia, stasis dermatitis, leg paresthesia, varicose veins, leg cramps, leg ulcer, obesity, leg hyperpigmentation, leg fatigue, leg pain, leg itching, lipodermatosclerosis, leg swelling and ⊕ brodie-Trendelenburg percussion test.

---

### Acetaminophen / aspirin / caffeine PO indications [^114rGmDA]. FDA (2025). Medium credibility.

Labeled indications
- Symptomatic relief of pain
- Symptomatic relief of headache
- Symptomatic relief of pain (in patients ≥ 12 years)
- Symptomatic relief of headache (in patients ≥ 12 years)
- Treatment of migraine

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^113NmQQw]. Journal of Vascular Surgery (2014). Medium credibility.

Multicomponent compression bandage (Guideline 5.3) states: We suggest the use of multicomponent compression bandage over single-component bandages for the treatment of venous leg ulcers. [GRADE - 2; LEVEL OF EVIDENCE - B] Evidence includes a large RCT with 245 patients showing improved healing at 24 weeks in the multilayer (4LB) bandage group versus single-layer (67% vs 49%; p = 0.009) and faster wound closure with 4LB (78 vs 168 days; p = 0.001); a meta-analysis of six trials with data from 797 patients found 30% improved healing with 4LB versus SSB (odds ratio, 1.31; 95% CI, 1.09–1.58; p = 0.005), though in countries familiar with SSB there was no significant difference after 3 months (33 of 53 = 62% healed with 4LB vs 43 of 59 = 73% with SSB); studies reported similar outcomes for proprietary and nonproprietary 4LB, a specific 4LB is not endorsed, and moderate-quality evidence supports multicomponent over single component compression.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^112xTcaL]. Journal of Vascular Surgery (2014). Medium credibility.

Guideline 5.1 — Compression for ulcer healing — recommendation: In a patient with a venous leg ulcer, we recommend compression therapy over no compression therapy to increase venous leg ulcer healing rate (GRADE - 1; LEVEL OF EVIDENCE - A).

---

### Global vascular guidelines on the management of chronic limb-threatening ischemia [^114aQ8nP]. Journal of Vascular Surgery (2019). High credibility.

Bhatt 2006 — clopidogrel plus low-dose aspirin vs placebo plus low-dose aspirin: In 15,603 patients with clinically evident cardiovascular disease (CVD) or multiple risk factors, a large randomized controlled trial reported that the primary efficacy end point (composite of myocardial infarction, stroke, or death from CV causes) occurred in 6.8% vs 7.3% (RR, 0.93; 95% CI, 0.83–1.05; p = 0.22), and the principal secondary efficacy end point (including hospitalizations for ischemic events) was 16.7% vs 17.9% (RR, 0.92; 95% CI, 0.86–0.995; p = 0.04).

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^1115ccW4]. Journal of Vascular Surgery (2014). Medium credibility.

Wound care — field evolution — notes that "the wound care field continues to evolve and expand", driven by "an aging society, increasing prevalence of obesity and other comorbid" factors.

---

### The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum [^115BcyyF]. Journal of Vascular Surgery (2011). Medium credibility.

Chronic venous insufficiency (meta‑analysis) — A meta‑analysis of SEPS studies published between 1985 and 2008 concluded that SEPS, used as part of a regimen for severe chronic venous insufficiency (CVI), benefits most patients in the short‑term for ulcer healing and prevention of recurrence, is safe with fewer perioperative complications than the classic Linton procedure, and that further prospective RCTs are needed to define long‑term benefits.

---

### Compression therapy after invasive treatment of superficial veins of the lower extremities: clinical practice guidelines of the American Venous Forum, Society for Vascular Surgery, American college of phlebology, Society for Vascular Medicine, and International Union of Phlebology [^111YeNGT]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2019). High credibility.

Regarding nonpharmacologic interventions for chronic venous insufficiency, more specifically with respect to compression stockings, after interventional treatment, ACP/AVF/IUP/SVM/SVS 2019 guidelines recommend to consider offering compression therapy immediately after treatment of superficial veins with sclerotherapy to improve outcomes of sclerotherapy.

---

### The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum [^113W4FJd]. Journal of Vascular Surgery (2011). Medium credibility.

Chronic venous insufficiency (Dutch SEPS RCT) — Compared with medical treatment in 97 patients, surgical treatment (SEPS with or without superficial reflux ablation) in 103 patients yielded ulcer healing at 29 months of 83% with recurrence 22% versus 73% healing and 23% recurrence in the conservative group (P = NS); the study concluded that SEPS, with or without superficial ablation, failed to improve healing or recurrence over best medical treatment, with subgroup benefit in medial/recurrent ulcers or centers of excellence, and 86% of patients had medial or recurrent ulcers; evidence summaries concluded properly conducted RCTs are needed for perforator interruption efficacy.

---

### Editor's choice-European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs [^115YLkhg]. European Journal of Vascular and Endovascular Surgery (2022). High credibility.

Regarding therapeutic procedures for chronic venous insufficiency, more specifically with respect to indications for interventional treatment, ESVS 2022 guidelines recommend to offer interventional treatment of venous incompetence in patients with superficial venous incompetence, presenting with skin changes as a result of chronic venous disease (CEAP clinical class C4-C6).

---

### Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report [^115z3V86]. Chest (2021). High credibility.

Regarding medical management for deep vein thrombosis, more specifically with respect to choice of anticoagulation, extended therapy, ACCP 2021 guidelines recommend to administer reduced-dose DOACs rather than aspirin in patients requiring extended-phase anticoagulation.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^1114t8Zi]. Journal of Vascular Surgery (2014). Medium credibility.

Non-graded practice statements — the guideline notes that "Such recommendations are not graded but deemed by the guideline developers to be necessary to provide a comprehensive guideline that encompasses all the details needed for providing care for patients with venous ulcers".

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^115hA5Vb]. Journal of Vascular Surgery (2014). Medium credibility.

Guideline 4.17 — Anti-inflammatory therapies — recommendation: We suggest against use of anti-inflammatory therapies for the treatment of venous leg ulcers (GRADE - 2; LEVEL OF EVIDENCE - C).

---

### Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [^113ei3ic]. Chest (2012). Medium credibility.

Peripheral artery disease — prostanoids for critical leg ischemia/rest pain: For patients with symptomatic peripheral artery disease (PAD) and critical leg ischemia/rest pain who are not candidates for vascular intervention, the guideline states "we suggest the use of prostanoids in addition to previously recommended antithrombotic therapies (aspirin 75–100 mg daily or clopidogrel 75 mg daily) (Grade 2C)". A Cochrane review of 13 studies found prostanoids improved rest pain and ulcer healing (77 and 136 patients per 1,000 treated, respectively) but did not significantly prevent amputations or decrease mortality; tolerability was poor, with ~75% experiencing at least one adverse event vs 31% of controls, and the most commonly reported adverse effects were headache, nausea, vomiting, diarrhea, and facial flushing. Values and preferences note that patients who do not value uncertain relief of rest pain and ulcer healing greater than avoidance of a high likelihood of drug-related side effects will be disinclined to undergo prostanoid therapy.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^1111Fi8m]. Journal of Vascular Surgery (2014). Medium credibility.

Guideline 8.4 — Primary prevention with education measures states that in patients with C1–4 disease, we suggest patient and family education, regular exercise, leg elevation when at rest, careful skin care, weight control, and appropriately fitting foot wear [BEST PRACTICE]. Supporting statements note that leg elevation is effective in patients with C4 disease by increasing microcirculatory flow and that a prospective study of exercise in 20 patients showed improvement in calf muscle pump function in C5 patients. Although no data exist for educational interventions in those with chronic venous insufficiency (CVI) to prevent venous leg ulcer (VLU), it is recommended that all vascular specialists make the effort to educate primary caregivers.

---

### 2016 AHA / ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary [^111e4hhq]. Vascular Medicine (2017). Medium credibility.

Wound healing therapies for critical limb ischemia (CLI) — an interdisciplinary care team should evaluate and provide comprehensive care for patients with CLI and tissue loss to achieve complete wound healing and a functional foot; in patients with CLI, wound care after revascularization should be performed with the goal of complete wound healing; in patients with CLI, intermittent pneumatic compression (arterial pump) devices may be considered to augment wound healing and/or ameliorate severe ischemic rest pain; in patients with CLI, the effectiveness of hyperbaric oxygen therapy for wound healing is unknown; and prostanoids are not indicated in patients with CLI.

---

### Editor's choice-European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs [^115DuKfa]. European Journal of Vascular and Endovascular Surgery (2022). High credibility.

Regarding medical management for chronic venous insufficiency, more specifically with respect to venoactive agents, ESVS 2022 guidelines recommend to consider offering medical treatment with venoactive drugs to reduce venous symptoms and edema in patients with symptomatic chronic venous disease not undergoing interventional treatment, awaiting intervention, or experiencing persisting symptoms and/or edema after intervention.

---

### 2025 SCAI clinical practice guidelines for the management of chronic venous disease: this statement was endorsed by the Society for Vascular Medicine (SVM) [^111xa9KK]. Journal of the Society for Cardiovascular Angiography & Interventions (2025). High credibility.

Regarding nonpharmacologic interventions for chronic venous insufficiency, more specifically with respect to compression stockings, medically managed, SCAI 2025 guidelines recommend to consider offering compression therapy in patients with symptomatic varicose veins and/or chronic venous insufficiency.

---

### The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum [^1136Rjsk]. Journal of Vascular Surgery (2011). Medium credibility.

Chronic venous insufficiency (multicenter cohort) — In a large retrospective multicenter cohort, 832 patients with CEAP class C4 to C6 were monitored for 9 years after SEPS; only 55% underwent H/L/S in addition to SEPS, 92% of ulcers healed with only 4% recurrences, and the nonfatal complication rate was 3% with documented improvement in venous hemodynamics in a subset.

---

### Aspirin PR indications [^113nUPwG]. FDA (2025). Medium credibility.

Labeled indications
- Symptomatic relief of pain
- Symptomatic relief of fever

---

### The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum [^111xbemC]. Journal of Vascular Surgery (2011). Medium credibility.

Duplex scanning — We recommend that in patients with chronic venous disease, a complete history and detailed physical examination are complemented by duplex scanning of the deep and superficial veins, noting that the test is safe, noninvasive, cost-effective, and reliable; we recommend that a complete duplex exam include visualization, compressibility, venous flow with measurement of duration of reflux, and augmentation; we recommend eliciting reflux in the upright position either by increased intra-abdominal pressure using a Valsalva maneuver for the common femoral vein and saphenofemoral junction, or by manual or cuff compression and release of the limb distal to the point of examination for more distal veins; we recommend a cutoff value of 1 second for abnormally reversed flow in the femoral and popliteal veins and of 500 ms for the great saphenous, small saphenous, tibial, deep femoral, and perforating veins; and we recommend selective duplex scanning of perforating veins in chronic venous insufficiency with "pathologic" perforators defined by outward flow of ≥ 500 ms, diameter ≥ 3.5 mm, and location beneath healed or open venous ulcers (CEAP class C5-C6).

---

### Editor's choice-European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs [^116ADLQb]. European Journal of Vascular and Endovascular Surgery (2022). High credibility.

Regarding therapeutic procedures for chronic venous insufficiency, more specifically with respect to indications for interventional treatment, ESVS 2022 guidelines recommend to take into account other non-venous causes of edema before planning interventional treatment in patients with superficial venous incompetence presenting with edema (CEAP clinical class C3).

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^11472gLG]. Journal of Vascular Surgery (2014). Medium credibility.

Compression with arterial insufficiency (Guideline 5.4) states: In a patient with a venous leg ulcer and underlying arterial disease, we do not suggest compression bandages or stockings if the ankle-brachial index is 0.5 or less or if absolute ankle pressure is less than 60 mm Hg. [GRADE - 2; LEVEL OF EVIDENCE - C] An ABI of less than 0.5 is considered to be indicative of severe arterial disease.

---

### The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum [^1153UKAE]. Journal of Vascular Surgery (2011). Medium credibility.

Chronic venous disease — duplex reflux thresholds and perforator criteria: We recommend a cutoff value of 1 second for abnormally reversed flow (reflux) in the femoral and popliteal veins and of 500 ms for the great saphenous vein, the small saphenous vein, the tibial, deep femoral, and the perforating veins. We recommend that in patients with chronic venous insufficiency, duplex scanning of the perforating veins is performed selectively, and that the definition of pathologic perforators includes those with an outward flow of duration of > 500 ms, with a diameter of ≥ 3.5 mm and a location beneath healed or open venous ulcers (CEAP class C5-C6).

---

### Editor's choice-European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs [^113WCjC4]. European Journal of Vascular and Endovascular Surgery (2022). High credibility.

Regarding nonpharmacologic interventions for chronic venous insufficiency, more specifically with respect to compression stockings (post-thrombotic syndrome), ESVS 2022 guidelines recommend to consider offering adjuvant intermittent pneumatic compression to reduce its severity in patients with post-thrombotic syndrome.

---

### Society of Interventional Radiology position statement on the management of chronic iliofemoral venous obstruction with endovascular placement of metallic stents [^113RbfCi]. Journal of Vascular and Interventional Radiology (2023). High credibility.

Venous ulcers — patients with venous ulcers should receive compression therapy and close active follow-up, ideally in a specialized wound care facility that follows published clinical practice guidelines (Level of Evidence A, Strength of Recommendation Strong). Whether or not the endovascular physician is the primary provider of ulcer care, they should verify key elements are delivered, including compression therapy, wound bed preparation via absorptive dressings, oral pentoxifylline, antibiotics for wound infections or severe bacterial colonization guided by quantitative wound cultures, and wound debridement as needed. Depending on clinical assessment, early ablation of refluxing saphenous veins or treatment of large refluxing perforator veins directed toward an active ulcer bed may be considered, and poor healing or increased pain with compression can suggest venous outflow obstruction that should be evaluated.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^113tbfgu]. Journal of Vascular Surgery (2014). Medium credibility.

Guideline 4.18 — Indications for adjuvant therapies — recommendation: We recommend adjuvant wound therapy options for venous leg ulcers that fail to demonstrate improvement after a minimum of 4 to 6 weeks of standard wound therapy (GRADE - 1; LEVEL OF EVIDENCE - B).

---

### Global vascular guidelines on the management of chronic limb-threatening ischemia [^114UP5xE]. Journal of Vascular Surgery (2019). High credibility.

Chronic limb-threatening ischemia (CLTI) — post-healing foot protection: Provide counseling on continued protection of the healed wound and foot to include appropriate shoes, insoles, and monitoring of inflammation; this is graded 1 (Strong) with level of evidence A (High).

---

### Editor's choice-European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs [^114jEqom]. European Journal of Vascular and Endovascular Surgery (2022). High credibility.

Regarding specific circumstances for chronic venous insufficiency, more specifically with respect to patients on anticoagulants, ESVS 2022 guidelines recommend to do not interrupt anticoagulation in patients with chronic venous disease receiving anticoagulants and scheduled to undergo endovenous thermal ablation.

---

### Compression therapy after invasive treatment of superficial veins of the lower extremities: clinical practice guidelines of the American Venous Forum, Society for Vascular Surgery, American college of phlebology, Society for Vascular Medicine, and International Union of Phlebology [^114q9kHQ]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2019). High credibility.

Venous leg ulcers — compression therapy guidance states that current evidence supports using compression for ulcer healing. None of the publications to date specifically address the role and effectiveness of compression after treatment of superficial veins in patients with venous ulcers; therefore, it is reasonable and safe to follow recommendations for the entire population of patients with venous ulcers such that compression therapy should be recommended to increase venous leg ulcer healing rates and to decrease recurrence rates. Peripheral artery disease can coexist in up to 25% of patients with venous ulcers, and use of compression in patients with significantly compromised arterial perfusion of the limb is considered unsafe. The preferred practice is to limit the use of compression to patients with an ankle-brachial index exceeding 0.5 or if absolute ankle pressure is > 60 mm Hg.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^114C234W]. Journal of Vascular Surgery (2014). Medium credibility.

Nonvenous causes of leg ulcers (Guideline 3.2) — We recommend identification of medical conditions that affect ulcer healing and other nonvenous causes of ulcers. [BEST PRACTICE]

---

### Editor's choice-European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs [^113E7hb5]. European Journal of Vascular and Endovascular Surgery (2022). High credibility.

Regarding surgical interventions for chronic venous insufficiency, more specifically with respect to vein ligation and stripping, ESVS 2022 guidelines recommend to consider administering ultrasound-guided tumescent anesthesia as an alternative to general or regional anesthesia in patients with superficial venous incompetence undergoing high ligation/stripping.

---

### 2025 SCAI clinical practice guidelines for the management of chronic venous disease: this statement was endorsed by the Society for Vascular Medicine (SVM) [^112g4fye]. Journal of the Society for Cardiovascular Angiography & Interventions (2025). High credibility.

Accessory great saphenous vein (GSV) reflux — conditional recommendation and evidence: For patients with symptomatic accessory GSV reflux, the SCAI guideline panel suggests ablation therapy plus compression as potentially more beneficial than conservative management alone (conditional recommendation, very low certainty of evidence). Remarks state that accessory veins encompass normal anatomic variants including the anterior and posterior accessory saphenous veins, which often run adjacent to the GSV, and some accessory GSV tributaries may not be treatable with ablation due to tortuosity or other anatomic considerations; the anterior and posterior accessory GSV were recently renamed anterior and posterior GSV, respectively. Evidence includes two RCTs and one NRS: the RCTs assessed time to ulcer healing and ulcer recurrence, the NRS reported ulcer healing without recurrence, and one RCT reported symptom improvement and quality of life; across included studies, ablation probably reduces median days to ulcer healing (MD, 31.73 fewer days; 95% CI, 45.1–18.3), with lower certainty because one RCT included few patients with symptomatic accessory GSV.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^112mypoi]. Journal of Vascular Surgery (2014). Medium credibility.

Venous leg ulcer pathophysiology knowledge — We recommend a basic practical knowledge of venous physiology and venous leg ulcer pathophysiology for all practitioners caring for venous leg ulcers. [BEST PRACTICE]

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^112aYozV]. Journal of Vascular Surgery (2014). Medium credibility.

Venous leg ulcer (VLU) débridement — We recommend that venous leg ulcers receive thorough débridement at their initial evaluation to remove obvious necrotic tissue, excessive bacterial burden, and cellular burden of dead and senescent cells [GRADE - 1; LEVEL OF EVIDENCE - B]. We suggest that additional maintenance débridement be performed to maintain the appearance and readiness of the wound bed for healing [GRADE - 2; LEVEL OF EVIDENCE - B], and we suggest that the health care provider choose from a number of débridement methods, including sharp, enzymatic, mechanical, biologic, and autolytic; more than one débridement method may be appropriate [GRADE - 2; LEVEL OF EVIDENCE - B].

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^115CaFA1]. Journal of Vascular Surgery (2014). Medium credibility.

Wound care — All therapies must be used concurrently with compression therapy or venous intervention to control the underlying venous hypertension resulting in ulceration, and evidence is sought for improvement in patient-centered outcomes such as pain reduction and wound healing.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^117KfKNL]. Journal of Vascular Surgery (2014). Medium credibility.

Venous leg ulcer — supporting evidence for patient selection in perforator interruption: A systematic review including 12 practice guidelines and four randomized controlled trials concluded that perforating vein interruption should be reserved for patients with large pathologic perforators with advanced chronic venous insufficiency, with evidence suggesting no added benefit in less severe disease (C2, C3); registry data associated ulcer healing with concomitant ablation of superficial reflux and lack of deep venous obstruction (P < .05).

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^114kj8fR]. Journal of Vascular Surgery (2014). Medium credibility.

Guideline 3.5: Wound biopsy — We recommend wound biopsy for leg ulcers that do not improve with standard wound and compression therapy after 4 to 6 weeks of treatment and for all ulcers with atypical features [GRADE - 1; LEVEL OF EVIDENCE - C]. The biopsy specimen should be obtained from several sites, including the wound edge and central provisional matrix, and another consideration for tissue biopsy independent of time frame is differentiation of other possible nonvenous causes for leg ulcer.

---

### Compression therapy after invasive treatment of superficial veins of the lower extremities: clinical practice guidelines of the American Venous Forum, Society for Vascular Surgery, American college of phlebology, Society for Vascular Medicine, and International Union of Phlebology [^1152GWrp]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2019). High credibility.

Regarding nonpharmacologic interventions for chronic venous insufficiency, more specifically with respect to compression stockings, after interventional treatment, ACP/AVF/IUP/SVM/SVS 2019 guidelines recommend to use the best clinical judgment to determine the duration of compression therapy after treatment.

---

### The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum [^116ebnxM]. Journal of Vascular Surgery (2011). Medium credibility.

Chronic venous insufficiency (systematic review) — In a systematic review of SEPS (with or without superficial ablation), ulcers in 88% of limbs healed and recurred in 13% at a mean time of 21 months; risk factors for nonhealing/recurrence included postoperative incompetent perforators, pathophysiologic obstruction, previous DVT, and ulcer diameter > 2 cm, and "surgical treatment, including SEPS, with or without saphenous ablation, is recommended for patients with venous ulcers, but RCTs are needed to discern the contributions of compression therapy, superficial venous surgery, and SEPS in patients with advanced CVI".

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^111gzTf7]. Journal of Vascular Surgery (2014). Medium credibility.

Perforator venous reflux and venous leg ulcer — an RCT comparing SEPS (with or without superficial reflux ablation) to medical treatment "found no difference in healing rate or recurrence in the two treatment groups", though "patients with recurrent ulceration or medially located ulcers in the surgical group had a longer ulcer-free period than did those treated in the conservative group (P = 0.02)". A secondary analysis of the Dutch SEPS trial reported "on 94 ulcerated legs" with "a mean follow-up of 29 months", and "Ulcer recurrence was significantly higher in patients who had an incomplete SEPS procedure (P = 0.007)".

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^114X9ArX]. Journal of Vascular Surgery (2014). Medium credibility.

Superficial venous surgery vs compression — evidence strength: For ulcer healing, the strength and grade of evidence favoring surgery are limited to a Grade 2C classification, whereas for prevention of ulcer recurrence each study favored surgery plus compression over compression alone to a statistically significant degree and the strength and grade of evidence is 1B.

---

### Varicose veins: diagnosis and treatment [^113xPezQ]. American Family Physician (2019). High credibility.

Regarding nonpharmacologic interventions for varicose veins, more specifically with respect to compression therapy, primary/preprocedural, AAFP 2019 guidelines recommend to insufficient evidence to recommend compression stockings for the treatment of varicose veins in the absence of active or healed venous ulcers.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^11663qR5]. Journal of Vascular Surgery (2014). Medium credibility.

Compression therapy for ulcer recurrence (Guideline 5.2) states: In a patient with a healed venous leg ulcer, we suggest compression therapy to decrease the risk of ulcer recurrence. [GRADE - 2; LEVEL OF EVIDENCE - B] Recurrence risk is substantial and reduced by compression, with one study showing a 67% recurrence rate with 35% having four or more episodes, a study reporting recurrence of 28% with compression alone versus 12% with superficial venous surgery, and an RCT in which high-pressure compression hosiery (34–46 mm Hg) reduced recurrence at 6 months versus no compression (RR, 0.46; 95% CI, 0.27–0.76; p = 0.003); compliance is important, with inability to tolerate compression associated with recurrent ulceration (RR, 2.58; 95% CI, 1.33–5.01; p = 0.010) and observational data showing 16% recurrence with compliance versus 100% without (P < .0001).

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^1164Gysf]. Journal of Vascular Surgery (2014). Medium credibility.

Venous leg ulcer manual lymphatic drainage — We suggest against adjunctive lymphatic drainage for healing of the chronic venous leg ulcers. [GRADE - 2; LEVEL OF EVIDENCE - C]

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^112vhq8R]. Journal of Vascular Surgery (2014). Medium credibility.

Compression — ulcer healing (Guideline 5.1) states: "In a patient with a venous leg ulcer, we recommend compression therapy over no compression therapy to increase venous leg ulcer healing rate. [GRADE - 1; LEVEL OF EVIDENCE - A]".

---

### Global vascular guidelines on the management of chronic limb-threatening ischemia [^111LDCZE]. Journal of Vascular Surgery (2019). High credibility.

Claudication undergoing endovascular revascularization — double-blinded, placebo-controlled RCT of clopidogrel plus aspirin versus aspirin alone in 132 patients found greater platelet inhibition with clopidogrel, with stimulated fibrinogen binding suppressed by 53.9%, 51.7%, and 57.2% at 1 hour, 24 hours, and 30 days, respectively (all P < .001).

---

### Global vascular guidelines on the management of chronic limb-threatening ischemia [^115wMUo4]. Journal of Vascular Surgery (2019). High credibility.

Recommendations 10.14–10.15 for wound care in chronic limb-threatening ischemia (CLTI) direct: 10.14 Provide mechanical offloading as a primary component for care of all CLTI patients with pedal wounds, graded 1 (Strong) with A (High) level of evidence; and 10.15 Provide counseling on continued protection of the healed wound and foot to include appropriate shoes, insoles, and monitoring of inflammation, graded 1 (Strong) with A (High) level of evidence.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^115d4HUA]. Journal of Vascular Surgery (2014). Medium credibility.

GRADE recommendations — venous leg ulcer guideline categories and implications are defined as follows: 1A is "Strong recommendation, high-quality evidence" and implies "Strong recommendation, can apply to most patients in most circumstances without reservation"; 1B is "Strong recommendation, moderate-quality evidence" and implies "Strong recommendation, can apply to most patients in most circumstances without reservation"; 1C is "Strong recommendation, low-quality or very-low-quality evidence" and implies "Strong recommendation but may change when higher quality evidence becomes available"; 2A is "Weak recommendation, high-quality evidence" and implies "Weak recommendation, best action may differ depending on circumstances or patients' or societal values"; 2B is "Weak recommendation, moderate-quality evidence" and has the same implication that "Weak recommendation, best action may differ depending on circumstances or patients' or societal values"; 2C is "Weak recommendation, low-quality or very-low-quality evidence" and implies "Very weak recommendations; Other alternatives may be reasonable".

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^115MgJjX]. Journal of Vascular Surgery (2014). Medium credibility.

Wound biopsy (Guideline 3.5) — We recommend wound biopsy for leg ulcers that do not improve with standard wound and compression therapy after 4 to 6 weeks of treatment and for all ulcers with atypical features. [GRADE - 1; LEVEL OF EVIDENCE - C]

---

### Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [^1155nEWZ]. Chest (2012). Medium credibility.

Critical leg ischemia/rest pain in symptomatic PAD not candidates for vascular intervention: The guideline states "we suggest the use of prostanoids in addition to previously recommended antithrombotic therapies (aspirin 75–100 mg daily or clopidogrel 75 mg daily) (Grade 2C)". Values and preferences note that "Patients who do not value uncertain relief of rest pain and ulcer healing greater than avoidance of a high likelihood of drug-related side effects will be disinclined to take prostanoids".

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^1178nMsL]. Journal of Vascular Surgery (2014). Medium credibility.

Venous leg ulcers — Guideline 4.18 indications for adjuvant therapies — We recommend adjuvant wound therapy options for VLUs that fail to demonstrate improvement after a minimum of 4 to 6 weeks of standard wound therapy [GRADE - 1; LEVEL OF EVIDENCE - B]. Failure to demonstrate improvement after 4 weeks with a decrease in wound size of at least 30% to 40% should lead the clinician to consider adjunctive treatment options.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^115gbdyc]. Journal of Vascular Surgery (2014). Medium credibility.

Guideline 5.2 — Compression for ulcer recurrence — recommendation: In a patient with a healed venous leg ulcer, we suggest compression therapy to decrease the risk of ulcer recurrence (GRADE - 2; LEVEL OF EVIDENCE - B).

---

### The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum [^111ZaLCm]. Journal of Vascular Surgery (2011). Medium credibility.

Pentoxifylline for venous leg ulcers — Randomized evidence reports that in a double-blind, placebo-controlled trial, complete healing occurred in 64% with pentoxifylline versus 53% with placebo without a statistically significant difference; another RCT in 133 patients found that 800 mg three times daily healed faster than placebo (P = 0.043) with median times 100, 83, and 71 days for placebo, pentoxifylline 400 mg, and pentoxifylline 800 mg three times daily, respectively, noting the higher dose was more effective but with more gastrointestinal upset and concluding pentoxifylline accelerates leg-ulcer healing; a more recent RCT showed increased healing vs placebo significant only on adjusted analysis (P = 0.046), and prior ACCP guidance suggests pentoxifylline 400 mg three times daily as adjunctive therapy (GRADE 2B).

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^111HjB8s]. Journal of Vascular Surgery (2014). Medium credibility.

Clinical evaluation (Guideline 3.1) — We recommend that for all patients with suspected leg ulcers fitting the definition of venous leg ulcer, clinical evaluation for evidence of chronic venous disease be performed. [BEST PRACTICE]

---

### Editor's choice-European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs [^116C5YMA]. European Journal of Vascular and Endovascular Surgery (2022). High credibility.

Regarding therapeutic procedures for chronic venous insufficiency, more specifically with respect to indications for interventional treatment, ESVS 2022 guidelines recommend to offer interventional treatment in patients with superficial venous incompetence presenting with symptomatic varicose veins (CEAP clinical class C2S).

---

### Global vascular guidelines on the management of chronic limb-threatening ischemia [^115y9Nv7]. Journal of Vascular Surgery (2019). High credibility.

Antithrombotic Trialists' Collaboration meta-analysis — aspirin allocation in randomized trials across primary and secondary prevention — reports that in the primary prevention trials, aspirin allocation yielded a 12% proportional reduction in serious vascular events (0.51% aspirin vs 0.57% control per year; p = 0.0001) but increased major gastrointestinal and extracranial bleeds (0.10% vs 0.07% per year; P < .0001). In the secondary prevention trials, aspirin allocation yielded a greater absolute reduction in serious vascular events (6.7% vs 8.2% per year; P < .0001), with reductions of about a fifth in total stroke (2.08% vs 2.54% per year; p = 0.002) and in coronary events (4.3% vs 5.3% per year; P < .0001). Absolute reductions in serious vascular events per 1000 were 36 in previous myocardial infarction, 38 in acute myocardial infarction, 36 in previous stroke or transient ischemic attack, 9 in acute stroke, and 22 in other high-risk patients, and proportional reductions seemed similar for men and women.

---

### Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report [^113udtMh]. Chest (2021). High credibility.

Regarding medical management for deep vein thrombosis, more specifically with respect to aspirin for extended treatment, ACCP 2021 guidelines recommend to consider initiating aspirin to prevent recurrent VTE in patients with unprovoked proximal DVT after stopping anticoagulant therapy and not having contraindications to aspirin.

---

### The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum [^114nJWWA]. Journal of Vascular Surgery (2011). Medium credibility.

Partsch systematic review — compression strength and recurrence: The review confirmed (GRADE 1A) that compression bandaging promotes healing of venous ulcers and that strong-compression hosiery (30 to 40 mm Hg) is more effective than medium- or low-compression stockings (GRADE 1B), and it observed GRADE 1A evidence that 30 to 40 mm Hg compression hosiery prevents recurrence of ulceration after healing.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^114cj2JV]. Journal of Vascular Surgery (2014). Medium credibility.

Guideline 6.17 — proximal chronic total venous occlusion/severe stenosis (bilateral or unilateral) with recalcitrant VLU, adjunctive arteriovenous fistula (AVF): "For those patients who would benefit from an open bypass, we suggest the addition of an adjunctive arteriovenous fistula (4–6 mm in size) as an adjunct to improve inflow into autologous or prosthetic crossover bypasses when the inflow is judged to be poor to aid in venous leg ulcer healing and to prevent recurrence. [GRADE - 2; LEVEL OF EVIDENCE - C]" Safety cautions include that "An arteriovenous fistula can produce distal venous hypertension if the fistulas are too large", and "use of an arteriovenous fistula should be temporary and its size should be controlled to avoid excessive flow", with technique noting "A suitably sized prosthetic sleeve around the fistula is one method to achieve this effect and allows later percutaneous closure with coil".

---

### Editor's choice-European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs [^112aEPkB]. European Journal of Vascular and Endovascular Surgery (2022). High credibility.

Regarding therapeutic procedures for chronic venous insufficiency, more specifically with respect to indications for interventional treatment, ESVS 2022 guidelines recommend to consider offering in patients with advanced skin changes (CEAP clinical class C4b, C5 or C6) with isolated or residual incompetent perforating veins thought to be significant.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^114p4RKr]. Journal of Vascular Surgery (2014). Medium credibility.

Guideline 4.22 — frequency of cellular therapy application for venous leg ulcers: We suggest reapplication of cellular therapy as long as the venous leg ulcer continues to respond on the basis of wound documentation [GRADE - 2; LEVEL OF EVIDENCE - C], and current clinical practice has included a period of 1 to 3 weeks of observation to determine effectiveness before reapplication is considered.

---

### Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [^114NhfmU]. Chest (2012). Medium credibility.

Aspirin — preventive limits and rescue dosing — Only a fraction (usually one-fourth to one-third) of all vascular complications can be prevented by aspirin alone, and there is no evidence that patients who experience a thrombotic event despite aspirin therapy benefit from treatment with higher-dose aspirin.

---

### The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum [^114auACD]. Journal of Vascular Surgery (2011). Medium credibility.

Compression therapy — CVI (CEAP classes C3-C6) and venous ulcers: Compression therapy remains the standard of care for advanced chronic venous disease and venous ulcers (class C3-C6), improves calf muscle pump function and decreases reflux in patients with chronic venous insufficiency, and graded compression is effective as primary treatment to aid healing and as adjuvant therapy to prevent recurrence; the Guideline Committee recommends compression therapy for patients with CVI (class C3-C6) and considers it the primary therapy to aid in healing venous ulcers (GRADE 1B) and the adjuvant therapy to superficial venous ablation to prevent ulcer recurrence (GRADE 1A).

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^115k8AHQ]. Journal of Vascular Surgery (2014). Medium credibility.

Guideline 4.22 — Frequency of cellular therapy application — recommendation: We suggest reapplication of cellular therapy as long as the venous leg ulcer continues to respond on the basis of wound documentation (GRADE - 2; LEVEL OF EVIDENCE - C).

---

### 2025 SCAI clinical practice guidelines for the management of chronic venous disease: this statement was endorsed by the Society for Vascular Medicine (SVM) [^115Rmpjw]. Journal of the Society for Cardiovascular Angiography & Interventions (2025). High credibility.

Venous ulcer compression therapy — evidence summary reports that eight RCTs assessed the rate of wound healing at 12 months with compression therapy and five RCTs measured time to wound healing at 12 months; compression bandages or stockings were associated with a probable increase in the rate of ulcer healing compared to no compression at 12 months (RR, 1.77; 95% CI, 1.41–2.21), corresponding to 311 more wounds healed per 1000 patients (95% CI, 166–489), and time to wound healing showed benefit in data synthesized from 5 RCTs (HR, 2.17; 95% CI, 1.59–3.10).

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^113q5E6y]. Journal of Vascular Surgery (2014). Medium credibility.

Guideline 6.17 — proximal chronic total venous occlusion/severe stenosis with recalcitrant venous ulcer — adjunctive arteriovenous fistula: For patients who would benefit from an open venous bypass, we suggest the addition of an adjunctive arteriovenous fistula (4–6 mm in size) to improve inflow into autologous or prosthetic crossover bypasses when inflow is judged to be poor to aid in venous leg ulcer healing and to prevent recurrence [GRADE - 2; LEVEL OF EVIDENCE - C].

---

### Compression therapy after invasive treatment of superficial veins of the lower extremities: clinical practice guidelines of the American Venous Forum, Society for Vascular Surgery, American college of phlebology, Society for Vascular Medicine, and International Union of Phlebology [^114RY73w]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2019). High credibility.

Regarding nonpharmacologic interventions for venous leg ulcer, more specifically with respect to compression therapy, ACP/AVF/IUP/SVM/SVS 2019 guidelines recommend to offer compression therapy to increase venous leg ulcer healing rate and to decrease the risk of ulcer recurrence in patients with a venous leg ulcer.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^116jnriK]. Journal of Vascular Surgery (2014). Medium credibility.

Guideline 5.5: Intermittent pneumatic compression (IPC) — the guideline states, "We suggest use of intermittent pneumatic compression when other compression options are not available, cannot be used, or have failed to aid in venous leg ulcer healing after prolonged compression therapy. [GRADE - 2; LEVEL OF EVIDENCE - C]". Supporting data are limited; to date, only 387 patients have been enrolled in RCTs comparing IPC with other treatment modalities, and whereas it is advantageous to use IPC compared with no compression therapy, currently there is limited evidence to suggest that the addition of IPC to compression therapy offers benefit. Patients likely to benefit most are those who cannot tolerate or do not have access to compression therapy or who have failed to respond to prolonged compression therapy alone. When IPC is used, there is some evidence that the proportion of ulcers healed (86% vs 61% at 6 months; p = 0.003) is improved with rapid compared with slow cycling.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^111KdU8S]. Journal of Vascular Surgery (2014). Medium credibility.

Laboratory evaluation (Guideline 3.6) — We suggest laboratory evaluation for thrombophilia for patients with a history of recurrent venous thrombosis and chronic recurrent venous leg ulcers. [GRADE - 2; LEVEL OF EVIDENCE - C]

---

### Editor's choice-European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs [^1123hFTC]. European Journal of Vascular and Endovascular Surgery (2022). High credibility.

Regarding therapeutic procedures for chronic venous insufficiency, more specifically with respect to considerations for interventional treatment (anesthesia), ESVS 2022 guidelines recommend to administer ultrasound-guided tumescent anesthesia in patients with superficial venous incompetence undergoing endovenous thermal ablation.

---

### Aspirin PO indications [^112PpSbE]. FDA (2025). Medium credibility.

Labeled indications
- Symptomatic relief of fever
- Symptomatic relief of pain
- Symptomatic relief of headache
- Treatment of AIS
- Secondary prevention of cardiovascular events, after PCI
- Treatment of NSTEMI
- Treatment of angina pectoris
- Treatment of STEMI
- Prevention of cardiovascular events in patients with coronary artery disease
- Prevention of cardiovascular events, after CABG surgery
- Prevention of cardiovascular events, during carotid endarterectomy
- Secondary prevention of AIS
- Secondary prevention of TIA
- Secondary prevention of myocardial infarction
- Treatment of TIA

Off-label indications
- Prevention of prosthetic valve thrombosis (bridging)
- Prevention of CRC (in patients 50–69 years)
- Prevention of preeclampsia in pregnant females
- Prevention of preeclampsia in pregnant females with diabetes mellitus
- Prevention of thrombosis in patients with antiphospholipid syndrome (asymptomatic)
- Prevention of myocardial infarction in patients with carotid artery stenosis
- Treatment of migraine attacks
- Prevention of cardiovascular events in patients with PAD
- Treatment of acute pericarditis
- Treatment of recurrent pericarditis
- Prevention of thrombosis in patients with FMD
- Treatment of giant cell arteritis
- Prevention of thrombosis in patients with polycythemia vera
- Prevention of thrombosis in patients with renal artery aneurysm

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^1145zHJQ]. Journal of Vascular Surgery (2014). Medium credibility.

Wound bed preparation — Wound bed preparation is defined as the management of the wound to accelerate endogenous healing and to facilitate the effectiveness of other therapeutic measures, with the aim to convert the molecular and cellular environment of a chronic wound to that of an acute healing wound; included within this framework are (1) debridement, (2) wound exudate control, and (3) management of surface bacteria, and control of these factors must also be achieved to stimulate optimal wound healing.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^114RW6Pf]. Journal of Vascular Surgery (2014). Medium credibility.

Venous leg ulcers — Guideline 4.17 anti-inflammatory therapies — We suggest against use of anti-inflammatory therapies for the treatment of venous leg ulcers (VLUs) [GRADE - 2; LEVEL OF EVIDENCE - C].

---

### Treatment… [^114pr4mw]. AAFP (2019). Medium credibility.

Intermittent Pneumatic Compression. Intermittent pneumatic compression may be considered when there is generalized, refractory edema from venous insufficiency; lymphatic obstruction; and significant ulceration of the lower extremity. Although intermittent pneumatic compression is more effective than no compression, its effectiveness compared with other forms of compression is unclear. Intermittent pneumatic compression may improve ulcer healing when added to layered compression. 30, 34. EXERCISE A systematic review evaluating progressive resistance exercise, resistance exercise plus prescribed physical activity, only walking, and only ankle exercises found that progressive resistance exercise with prescribed physical activity may result in an additional nine to 45 venous ulcers healed per 100 patients.
36. 38 MEDICATIONS Pentoxifylline.

This hemorheologic agent affects microcirculation and oxygenation, and can be used effectively as monotherapy or with compression therapy for venous ulcers. 1, 39 In seven randomized controlled trials, pentoxifylline plus compression improved healing of venous ulcers compared with placebo plus compression. Four trials showed that pentoxifylline alone improved healing compared with placebo alone. 19 Common adverse effects of pentoxifylline include nausea, gastrointestinal discomfort, headaches, dizziness, and prolonged bleeding time. Statins. Statins have vasoactive and anti-inflammatory effects. In a small study, patients receiving simvastatin, 40 mg once daily, had a higher rate of ulcer healing than matched patients given placebo.
42. Phlebotonics. These venoactive drugs theoretically work by improving venous tone and decreasing capillary permeability. Common drugs in this class include saponins, flavonoids, and micronized purified flavonoid fraction. 43 Although phlebotonics may improve edema and other signs and symptoms of chronic venous insufficiency, there was no difference in venous ulcer healing when compared with placebo.
44. 53 Recent trials show faster healing of venous ulcers when early endovenous ablation to correct superficial venous reflux is performed in conjunction with compression therapy, compared with compression alone or with delayed intervention if the ulcer did not heal after six months. 21 The most common complications of endovenous ablation were pain and deep venous thrombosis. 21.

---

### Global vascular guidelines on the management of chronic limb-threatening ischemia [^114YLaro]. Journal of Vascular Surgery (2019). High credibility.

Recommendation 4.3 — antiplatelet therapy effects — A meta-analysis of 287 studies involving 135,000 patients in comparisons of antiplatelet therapy vs control and 77,000 in comparisons of different antiplatelet regimens reported that allocation to antiplatelet therapy reduced the combined outcome of any serious vascular event by about one-quarter.

---

### Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF / AHA guideline recommendations): a report of the American college of cardiology foundation / American Heart Association task force on practice guidelines [^112asdkE]. Journal of the American College of Cardiology (2013). Medium credibility.

Critical limb ischemia (CLI) medical and pharmacological treatment — effectiveness and roles — are summarized as: CLASS III Parenteral administration of pentoxifylline is not useful for the treatment of CLI (Level of Evidence: B); CLASS IIb Parenteral administration of PGE-1 or iloprost for 7 to 28 days may be considered to reduce ischemic pain and facilitate ulcer healing in patients with CLI, but its efficacy is likely to be limited to a small percentage of patients (Level of Evidence: A); CLASS III Oral iloprost is not an effective therapy to reduce the risk of amputation or death in patients with CLI (Level of Evidence: B); and CLASS IIb The efficacy of angiogenic growth factor therapy for treatment of CLI is not well established and is best investigated in the context of a placebo-controlled trial (Level of Evidence: C).

---

### 2025 SCAI clinical practice guidelines for the management of chronic venous disease: this statement was endorsed by the Society for Vascular Medicine (SVM) [^115escJa]. Journal of the Society for Cardiovascular Angiography & Interventions (2025). High credibility.

Compression therapy considerations — stronger compression therapy may be more effective for venous ulcers, compression therapy and comprehensive wound care are feasible and necessary, supplementary ablative therapy may be needed to achieve faster and higher rates of ulcer healing, compression probably improves wound healing particularly in advanced disease, and payors should support coverage for compression garments.

---

### Global vascular guidelines on the management of chronic limb-threatening ischemia [^112P7ha7]. Journal of Vascular Surgery (2019). High credibility.

Peripheral bypass graft antithrombotic therapy — effects on patency and bleeding: Two Cochrane reviews have supported the use of aspirin and other antiplatelets in maintaining lower extremity bypass graft patency, with greater benefits in prosthetic grafts. The randomized Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) trial showed that dual antiplatelet therapy with clopidogrel and aspirin significantly improved patency in prosthetic grafts but not in venous grafts, and this was accompanied by an increased risk of mild to moderate bleeding. Regarding anticoagulation, one study reported that vitamin K antagonists did not improve prosthetic graft patency although they were beneficial in venous conduits, while a single-center study suggested therapeutic vitamin K antagonists to prolong the patency of prosthetic grafts with low velocities.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^114byCVa]. Journal of Vascular Surgery (2014). Medium credibility.

Venous leg ulcer (VLU) systemic drug therapy — For long-standing or large venous leg ulcer, we recommend treatment with either pentoxifylline or micronized purified flavonoid fraction used in combination with compression therapy. [GRADE - 1; LEVEL OF EVIDENCE - B] Supporting data note sulodexide improved VLU healing in 235 patients treated for 3 months, while intravenous prostaglandin E1 reduced time to healing and improved complete healing rate but the constraint of intravenous infusion (3 hours daily for 6 weeks) makes this therapy difficult to recommend. For micronized purified flavonoid fraction, clinical outcome measures in five RCTs and a meta-analysis (723 patients involved) showed increased healing rate at 6 months with relative risk reduction was 32%; 95% CI, 3%-70%. For pentoxifylline, in nine RCTs (eight vs placebo) including a total of 572 patients, pentoxifylline combined with compression improved ulcer healing with a relative risk ratio compared with placebo of 1.4 [95% CI, 1.19–1.66].

---

### 2024 ACC / AHA / AACVPR / APMA / ABC / SCAI / SVM / SVN / SVS / SIR / VESS guideline for the management of lower extremity peripheral artery disease: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^1174ab4w]. Circulation (2024). High credibility.

Regarding nonpharmacologic interventions for chronic limb-threatening ischemia, more specifically with respect to intermittent pneumatic compression therapy, AACVPR/ABC/ACC/AHA/APMA/SCAI/SIR/SVM/SVN/SVS/VESS 2024 guidelines recommend to consider offering arterial intermittent pneumatic compression therapy to augment wound healing or ameliorate ischemic rest pain in patients with CLTI if revascularization is not an option.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^1162GNSQ]. Journal of Vascular Surgery (2014). Medium credibility.

Ancillary measures for venous leg ulcer healing — Ancillary measures to improve ulcer healing include adequate nutrition to provide sufficient vitamins, minerals, and protein to support the growth of granulation tissue. Pharmacologic adjuncts noted include that pentoxifylline and micronized purified flavonoid fraction, both in combination with compression therapy, have demonstrated a beneficial effect on ulcer healing, although these medications are not widely used. Physiotherapy is a useful ancillary measure to VLU healing.

---

### Editor's choice-European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs [^1123m13a]. European Journal of Vascular and Endovascular Surgery (2022). High credibility.

Regarding therapeutic procedures for chronic venous insufficiency, more specifically with respect to considerations for interventional treatment (anesthesia), ESVS 2022 guidelines recommend to consider administering buffered solutions to reduce periprocedural pain in patients with superficial venous incompetence undergoing tumescent anesthesia.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^1115tsQ8]. Journal of Vascular Surgery (2014). Medium credibility.

Chronic venous disease (CVD) and venous leg ulcers (VLU) — risk factors, genetic associations, and endothelial pathophysiology are outlined, noting that genetic and environmental factors influence the predisposition to and perpetuation of primary venous disease and that important observations are a family history, female gender, pregnancy, estrogen, prolonged standing, sitting postures, and obesity. Genetic conditions such as Klippel-Trénaunay syndrome, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), FOXC2 gene mutations, desmulin dysregulation, and Ehlers-Danlos syndrome display early onset of varicose veins; hemochromatosis C282Y (HFE) gene mutation and certain factor XIII V34L gene variants have been demonstrated in patients with CVD and varicose veins and may have long-term implications for increased risk of the more severe forms of CVD as well as the size of venous ulcers. Factor XIII is described as an important cross-linking protein that plays a key role during ulcer healing; after superficial venous surgery in patients with CVD, specific factor XIII genotypes had favorable ulcer healing rates whereas the HFE gene mutation had no influence on healing time. It is clear from biochemical, immunohistochemical, and functional studies that both the vein wall and the valve are involved in the primary events leading to venous disease, with perturbation in the microcirculation a critical component in the pathophysiologic process of CVD; the endothelium is a key regulator of vascular tone, hemostasis, and coagulation, and multiple injuries and risk conditions have an adverse effect on the endothelium that must compensate to maintain integrity of the vascular wall. In CVD, the sine qua non is persistent elevated ambulatory venous pressure, with shear stress on endothelial cells leading to release of vasoactive agents and expression of E-selectin, inflammatory molecules, chemokines, and prothrombotic precursors; mechanical forces, low shear stress, and stretch are sensed through intercellular adhesion molecule 1 (ICAM-1, CD54) and mechanosensitive transient receptor potential vanilloid channels, and patients with CVD have increased expression of ICAM-1.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^112CpX8n]. Journal of Vascular Surgery (2014). Medium credibility.

Venous leg ulcers (VLU) — inflammatory mediators and matrix remodeling — are characterized by expression of matrix metalloproteinases (MMPs) and cytokines that affect the venous wall and surrounding tissues, with high MMP levels and protease activity correlating with poor healing. Venous ulcer fibroblasts exhibit mitogen-activated protein kinase pathway alterations with overexpression of p38 that can be suppressed by fibroblast growth factor, and in a nonrandomized evaluation during compression therapy, unhealed ulcers typically displayed high proinflammatory cytokines; after 4 weeks of compression therapy, these levels decreased significantly and the wounds began to heal, with TGF-β1 increasing after compression. When cytokine levels were related to healing, those with higher levels of proinflammatory cytokines including interleukin-1 and interferon-γ healed significantly better than those with lower levels before compression. Hypoxia-related factors HIF-1α and HIF-2α were overexpressed in varicose veins from chronic venous disease patients. Structural remodeling includes overall increased collagen with decreased elastin and laminin; in smooth muscle from varicose veins, collagen type III decreases with increased type I, a profile also observed in dermal fibroblasts, and increased MMP-3 activity leads to post-translational modification of collagen type III that is reversible with MMP-3 inhibition in vitro. Venous hypertension, inflammation, and remodeling contribute to formation in the postcapillary venule of a fibrin cuff involving fibrin and collagen deposition, and MMPs are described as an important step in the development of primary venous disease leading to extracellular matrix degradation, structural vein wall changes and fibrosis, and tissue damage leading to venous ulceration.

---

### The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum [^117XyRQ5]. Journal of Vascular Surgery (2011). Medium credibility.

Diosmin and hesperidin (MPFF) and sulodexide for venous ulcers — In an RCT, among patients with ulcers measuring ≤ 10 cm, more ulcers healed with MPFF than with placebo (32% vs 13%; p = 0.028), with shorter healing duration (P = 0.037), and less sensation of heavy leg with MPFF (P = 0.030); a meta-analysis of five RCTs including 723 patients found that at 6 months the chance of healing was 32% better with adjunctive MPFF (relative risk reduction, 32%; 95% CI, 3%-70%); for persistent venous ulcers, MPFF (oral) or sulodexide (intramuscular then oral) are suggested in ACCP guidelines (GRADE 2B), and the SVS/AVF Guideline Committee also suggests MPFF or pentoxifylline as adjuvant therapy to compression (GRADE 2B).

---

### Compression therapy after invasive treatment of superficial veins of the lower extremities: clinical practice guidelines of the American Venous Forum, Society for Vascular Surgery, American college of phlebology, Society for Vascular Medicine, and International Union of Phlebology [^111WofVA]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2019). High credibility.

Compression after superficial vein treatment in patients with a venous leg ulcer — in a patient with a venous leg ulcer, we recommend compression therapy over no compression therapy to increase venous leg ulcer healing rate and to decrease the risk of ulcer recurrence [GRADE - 1; LEVEL OF EVIDENCE - B], and in a patient with a venous leg ulcer and underlying arterial disease, we suggest limiting the use of compression to patients with ankle-brachial index exceeding 0.5 or if absolute ankle pressure is > 60 mm Hg [GRADE - 2; LEVEL OF EVIDENCE - C].

---

### Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [^116dg9Fq]. Chest (2012). Medium credibility.

Arachidonic acid metabolism and aspirin mechanism — Arachidonic acid, a 20-carbon fatty acid containing four double bonds, is liberated from the sn2 position in membrane phospholipids and is converted by cytosolic prostaglandin H synthases to the unstable intermediate prostaglandin H2; the synthases are colloquially termed "cyclooxygenases" and exist in two forms, COX-1 and COX-2. Low-dose aspirin selectively inhibits COX-1, and high-dose aspirin inhibits both COX-1 and COX-2, and prostaglandin H2 is converted by tissue-specific isomerases to multiple prostanoids that activate specific cell membrane receptors.

---

### The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum [^113HutdT]. Journal of Vascular Surgery (2011). Medium credibility.

Chronic venous insufficiency (CEAP classes C5–C6) — In the North American SEPS registry across 17 U.S. centers (155 limbs; 85% class C5 and C6), ulcer healing at 1 year was 88% with a median time to healing of 54 days, and ulcer recurrence was 16% at 1 year and 28% at 2 years; among 27 class C6 patients treated with SEPS alone, the 2‑year ulcer recurrence rate was 35%, which was not significantly higher than in those who underwent SEPS and superficial ablation alone (25%).

---

### Compression therapy after invasive treatment of superficial veins of the lower extremities: clinical practice guidelines of the American Venous Forum, Society for Vascular Surgery, American college of phlebology, Society for Vascular Medicine, and International Union of Phlebology [^116Z8zno]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2019). High credibility.

Regarding nonpharmacologic interventions for chronic venous insufficiency, more specifically with respect to compression stockings, after interventional treatment, ACP/AVF/IUP/SVM/SVS 2019 guidelines recommend to use compression stockings providing pressures > 20 mmHg together with eccentric pads placed directly over the ablated or operated vein for postprocedural compression therapy in patients after ablation or surgery of the saphenous veins.

---

### The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum [^1126vCDN]. Journal of Vascular Surgery (2011). Medium credibility.

Varicose veins — CHIVA saphenous vein–preserving approach in randomized trials: two RCTs compared standard treatment with CHIVA; in a single-center RCT treating 47 legs with venous ulcers, at a mean follow-up of 3 years healing was 100% in the surgical group vs 96% with compression (median healing time 31 vs 63 days; P < .02) and recurrence was 9% vs 38% (P < .05), with exclusions including excessive ulcers (> 12 cm). In primary varicose veins, 501 patients were randomized to CHIVA, stripping with clinic marking, or stripping with duplex marking; the primary end point was recurrence within 5 years, CHIVA outcomes were 44.3% cure, 24.6% improvement, and 31.1% failure compared with 21.0%/26.3%/52.7% (clinic) and 29.3%/22.8%/47.9% (duplex), and odds of recurrence at 5 years were higher with stripping vs CHIVA (clinic OR 2.64 [95% CI, 1.76–3.97; P < .001]; duplex OR 2.01 [95% CI, 1.34–3.00; P < .001]). Despite these results, the page states that the performance by a few outstanding interventionists "does not support offering this procedure to all practitioners".

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^116cwTsc]. Journal of Vascular Surgery (2014). Medium credibility.

Randomized evidence — compression versus no compression — shows improved healing outcomes in venous leg ulcers. "A total of nine RCTs compare compression therapy to no compression therapy", including an RCT of "36 patients" where Unna boot dressings versus noncompressive bandages yielded "wound healing rates… improved by 0.07 cm2/day (P = 0.004)", with "more patients completed heal in the compression group (RR, 2.30; 95% CI, 1.29–4.10)". A Cochrane review "identified three RCTs encompassing a total of 177 patients", with one "44 patients" study showing benefit "at 8 weeks", while two studies of "49 and 84 patients" showed no difference "at 7 weeks and 6 months". Another RCT of "321 patients" found at "24 weeks" superior healing in compression arms "(72% SSB and 67% 4LB)… compared with the no-compression group (29%; P < .0001)". Additional trials include "53 patients" with short-stretch bandages versus usual care showing complete healing "at 3 months" of "71%" versus "25%", and a trial of "36 patients" with four-layer bandage reporting higher complete healing "at 3 months" with compression "(RR, 4.0; 95% CI, 1.35–11.82)".

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^116Chwbq]. Journal of Vascular Surgery (2014). Medium credibility.

Venous leg ulcer pathophysiology — we recommend a basic practical knowledge of venous physiology and venous leg ulcer pathophysiology for all practitioners caring for venous leg ulcers.

---

### Compression therapy after invasive treatment of superficial veins of the lower extremities: clinical practice guidelines of the American Venous Forum, Society for Vascular Surgery, American college of phlebology, Society for Vascular Medicine, and International Union of Phlebology [^111Hxgc9]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2019). High credibility.

Regarding nonpharmacologic interventions for chronic venous insufficiency, more specifically with respect to compression stockings, after interventional treatment, ACP/AVF/IUP/SVM/SVS 2019 guidelines recommend to consider offering compression therapy (either elastic stockings or wraps) after surgical or thermal procedures to eliminate varicose veins when possible.

---

### Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum [^115oZuYb]. Journal of Vascular Surgery (2014). Medium credibility.

Objective of SVS and AVF clinical practice guidelines for venous leg ulcer management — scope and aim: Prior SVS and AVF guidelines addressed varicose veins (2001) and early thrombus removal for acute venous thrombosis (2012), and the current guidelines state that the objective is to focus on complete management of VLUs at all levels of care based on strength and quality of supporting evidence to guide specific recommendations, contributing to a more complete evidence‑based strategy for patients with chronic venous disease.

---

### The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. part II: endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine [^112Lmh37]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2024). High credibility.

Sulodexide — clinical benefit in chronic venous disease (CVD) is summarized as follows: In adults with CVD any stage (n = 1901), sulodexide compared with none or heparan sulphate was associated with leg edema reduction and improvement in venous symptoms with a low risk of adverse events (3%) in a systematic review and meta-analysis of 13 studies. Another systematic review and meta-analysis reported placebo-controlled evidence across 45 RCTs and 18 observational studies with sulodexide, noting that sulodexide was at least as effective as pentoxifylline for ulcer healing and effective in improving venous symptoms and signs.